Advanced Filters
noise

Parkinson's Disease Clinical Trials

A listing of Parkinson's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 622 clinical trials
C Chadwick Prodromos, M.D.

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosomes for Parkinson's Disease

This trial will study the safety and efficacy of intranasal instillation of cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes for the treatment of Parkinson's Disease

years of age All Phase 1
H Hannah Babcock

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson's Disease (PD) in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant …

30 years of age All Phase 2
C Christina DCM Faria, Doctor

Effect of Training and Use of Cane on Gait in Individuals With Parkinson's Disease

Introduction: Although individuals with Parkinson's disease (PD) commonly use assistive devices, the effects of these devices on gait remain poorly understood. Furthermore, previous studies on this topic only investigated the immediate effects of device usage, and the investigated outcomes were predominately performance-based neglecting participant-centered outcomes. Objective: To investigate the effect …

40 years of age All Phase N/A
U Umesh Tulachan

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease

The main goal of this clinical trial is to learn about the safety and tolerability of GT-02287. The questions it aims to answer are: What medical problems do participants have when taking GT-02287? How is GT-02287 absorbed, distributed, and removed from the body of participants over time (pharmacokinetics)? Are there …

30 - 85 years of age All Phase 1

Ambroxol to Slow Progression in Parkinson Disease

This is a UK only clinical trial in patients with Parkinson's disease (PD) of a drug called ambroxol hydrochloride, which is an already licensed drug for the treatment of respiratory conditions (such as a common cold) in many European countries. The aim of this trial is to find out whether …

35 - 75 years of age All Phase 3
C Christoph Guger, PhD

Neurofeedback Rehabilitation With FES and VR for PD

recoveriX PRO system is a Brain-Computer Interface (BCI) device that combines Motor Imagination (MI), with Functional Electrical Stimulation (FES) and Virtual Reality (VR) as feedback devices. The user wears an electroencephalography (EEG) cap that registers the neural activity during the mental practice. This system allows the user to control the …

40 - 80 years of age All Phase N/A
L Laura Swink, PhD

Occupational Therapy Led Social Prescription for People With Parkinson Disease

Loneliness is an epidemic that the U.S. Surgeon General implored must be addressed by society as a whole. Increased loneliness (i.e., distressing feelings of isolation) in people with Parkinson's disease (PD) has a pervasive impact and is associated with worsened motor and non-motor symptoms, and quality of life. The investigators …

18 years of age All Phase N/A
F Frederik B Jensen, MSc

The Effects of 24-Weeks Community-based Brisk Walking in People With Parkinson's Disease

The goal of this clinical trial is to investigate if brisk walking can improve walking function in people with Parkinson's disease and what kind of brisk walking intervention that is most effective. The main questions are: If brisk walking can reduce self-perceived walking difficulty What type of exercise intervention is …

40 years of age All Phase N/A
K Kristin M. Satterfield, MD,PhD

First-in-Human Single and Multiple Dose of HL-400

This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics of HL-400 (a NLRP3 inhibitor) following oral single and multiple ascending dose administration.

18 - 65 years of age All Phase 1
Y Yea-Ru Yang, PhD

Cognitive-motor Training in Parkinson Disease

Literature reviews showed the cognitive-motor training that combines cognitive tasks may enhance cognitive functions more effectively than individual interventions. Stepping-based cognitive-motor training has been shown to improve cognitive functions, balance, and gait performance in older adults. However, there is insufficient research evidence on the impact and correlation of this training …

40 - 80 years of age All Phase N/A

Simplify language using AI